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Abstract
Background: Dendritic cell (DC) vaccines can induce antitumor immune responses in patients with malignant diseases,
while the most suitable DC culture conditions have not been established yet. In this study we compared monocyte
derived human DC from conventional cultures containing GM-CSF and IL-4/TNF-α (IL-4/TNF-DC) with DC generated
by the novel protocol using GM-CSF and IFN-α (IFN-DC).
Methods: To characterise the molecular differences of both DC preparations, gene expression profiling was performed
using Affymetrix microarrays. The data were conformed on a protein level by immunophenotyping, and functional tests
for T cell stimulation, migration and cytolytic activity were performed.
Results: Both methods resulted in CD11c+ CD86+ HLA-DR+ cells with a typical DC morphology that could efficiently
stimulate T cells. But gene expression profiling revealed two distinct DC populations.
Whereas IL-4/TNF-DC showed a higher expression of genes envolved in phagocytosis IFN-DC had higher RNA levels
for markers of DC maturity and migration to the lymph nodes like DCLAMP, CCR7 and CD49d. This different
orientation of both DC populations was confined by a 2.3 fold greater migration in transwell experiments (p = 0.01).
Most interestingly, IFN-DC also showed higher RNA levels for markers of NK cells such as TRAIL, granzymes, KLRs and
other NK cell receptors. On a protein level, intracytoplasmatic TRAIL and granzyme B were observed in 90% of IFN-
DC. This translated into a cytolytic activity against K562 cells with a median specific lysis of 26% at high effector cell
numbers as determined by propidium iodide uptake, whereas IL-4/TNF-DC did not induce any tumor cell lysis (p =
0.006). Thus, IFN-DC combined characteristics of mature DC and natural killer cells.
Conclusion: Our results suggest that IFN-DC not only stimulate adaptive but also mediate innate antitumor immune
responses. Therefore, IFN-DC should be evaluated in clinical vaccination trials. In particular, this could be relevant for
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patients with diseases responsive to a treatment with IFN-α such as Non-Hodgkin lymphoma or chronic myeloid
leukemia.
Background
Dendritic cells (DC) are specialized in antigen presenta-
tion which plays a key role in the initiation of primary
immune responses. Immature DC phagocyte and process
antigens and after maturation they stimulate antigen spe-
cific T cells. This is the prerequisite for orchestrating the
cellular and humoral immune response [1].
This unique role of DC in the activation of host defense
has made them a promising candidate for vaccination
against a wide range of infectious agents and tumor anti-
gens. DC can be generated by culturing monocytes in vitro
with medium containing interleukin (IL)-4 and granulo-
cyte-macrophage colony-stimulating factor (GM-CSF).
TNF-α or a mixture of different proinflammatory mole-
cules are needed to generate mature DC [2,3]. So far, the
therapeutic results observed in patients with malignancies
following vaccination with IL-4-DC are encouraging at
best [4,5]. Therefore, there is a particular need for culture
conditions facilitating the generation of more efficacious
DC.
Recently, several groups generated DC by culturing mono-
cytes in the presence of IFN-α and GM-CSF (IFN-DC) for
three days [6-11]. IFN-α is released in large amounts dur-
ing antiviral immune responses and is involved in the
activation of cells of the innate and adaptive immune sys-
tem [12]. In particular, IFN-α enhances the cytotoxic
capacity of NK cells. IFN-α has also been successfully used
for the treatment of patients with chronic myeloid leuke-
mia (CML) [13] and Non-Hodgkin lymphoma (NHL)
[14]. The therapeutical effects could be related to IFN-α
stimulated NK cells and DC. Therefore, it is conceiving
that IFN-DC would be more efficient for vaccination of
patients with NHL or CML.
In order to examine the differences between IFN-DC and
conventional IL-4/TNF-DC, we compared the morphol-
ogy, immunophenotype, functional efficacy and gene
expression profiles of these cell preparations with regard
to their usefullness in anti-tumor vaccination strategies.
Methods
Isolation and culture of cells
Mononuclear cells (PBMC) were obtained from buffy
coats of healthy individuals. Monocytes were isolated by
negative selection using a RosetteSep antibody cocktail
(Stemcell Technologies, Vancouver, Canada), according
to the manufacturer's protocol. The resulting cell popula-
tion after this procedure had a median purity of 72%
CD14+ monocytes.
IFN-DC were generated by culturing monocytes in plastic
flasks (BD Falcon, UK) for 3 days in serumfree X-VIVO 20
medium (BioWhitaker Europe, Belgium), supplemented
with 1000 U/ml IFN-α (IntronA, Griffith Micro Science,
Rantigny, France) and 1000 U/ml GM-CSF (Immunex,
Seattle, US). For the generation of IL-4/TNF-DC, mono-
cytes were cultured in serumfree medium containing 500
U/ml IL-4 (Promocell, Heidelberg, Germany) and 800 U/
ml GM-CSF for 5 days. The resulting immature DC were
further treated by a 2 day culture step with fresh medium
containing 1000 U/ml TNF-α (Sigma) and 800 U/ml GM-
CSF. For all experiments, IFN-DC and IL-4/TNF-DC were
used after a culture period of 3 and 7 days, respectively. If
not mentioned otherwise, preparations of both groups
were derived from different individuals. The viability of
cells was determined by Trypan blue exclusion.
Immunophenotypic analysis
Flow cytometry was performed on a FACScan flow cytom-
eter (BD Biosciences, San Jose, US). The following FITC or
PE labeled mouse antibodies were used: CD45, CD1a,
CD3, CD11c, CD14, CD19, CD40, CD49b, CD56, CD80,
CD83, CD86, CD123, HLA-DR, TRAIL, NKG2D, nonspe-
cific IgG1, IgG2a, a mixture of IgG1 and IgG2a (BD Bio-
sciences, San Jose, US), CD209 (Beckman Coulter,
Marseille, France) and GZMB (Hölzel Diagnostika, Köln,
Germany). For intracellular staining, cells were permeabi-
lized with BD Cytofix/Cytoperm (BD Bioscience, San Jose,
US) according to the manufacturer's guideline.
Analysis of DC functions
The allostimulatory capacity of DC was measured in an
allogeneic mixed leukocyte reaction (MLR). DC were
resuspended in RPMI 1640 medium (Biochrome, Berlin,
Germany), supplemented with 10% FCS (PAA, Pasching,
Austria), 2 mM Glutamine, 100 U/ml Penicillin and 100
μg/ml Streptomycin (Sigma) and irradiated with 30 Gy.
Different DC numbers were cultivated with 1 × 105 alloge-
neic PBMC of a healthy donor in a round-bottomed 96-
well plate (Corning, NY, US). Antibodies against CD28
and CD49d (BD Biosciences, San Jose, US) were added at
1 μg/ml. The cells were incubated for 4 days at 37°C. For
the last 20 h of the culture, 1 μCi/well of 3 [H]-Thymidin
(Amersham, Braunschweig, Germany) was added. Finally,
3 [H]-Thymidin uptake was measured on a β-scintillation
counter (Perkin Elmer, Shelton, CT, US). The stimulatory
capacity was expressed by the stimulation index SI = cpmJournal of Translational Medicine 2007, 5:46 http://www.translational-medicine.com/content/5/1/46
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of stimulated PBMC/cpm of unstimulated PBMC. Each
experiment was done in triplicates.
Induction of cytokine production in T cells by DC was
determined by intracellular staining. As described above,
1 × 105 freshly isolated PBMC were cocultured with 5 ×
104 DC per well in a 96-well plate for 3 days. To block pro-
tein secretion, 10 μg/ml BrefeldinA (Sigma) was added for
the last 4 hours of the culture period. Cells were harvested
and incubated with a FITC labelled anti CD3 antibody
(BD Bioscience, San Jose, US). Cells were then permeabi-
lized with BD Cytofix/Cytoperm solution, stained with PE
labelled anti IFN-γ or IL-4 antibodies (BD Biosciences, San
Jose, US) and analyzed by flow cytometry.
Migration of DC was measured in 24-well transwell cul-
ture chambers (Costar, Cambridge, MA, US) as previously
described [8,15]. The 8 μm-pore transwell filters were
briefly coated with 10 μg/cm2 fibronectin (Sigma). The
upper chamber compartment was loaded with 2.5 × 105
IFN-DC or IL-4/TNF-DC in 150 μl X-VIVO 20 medium.
The lower chamber compartment was filled with 500 μl
medium supplemented with 100 ng/ml recombinant
Mip-3β (Promocell, Heidelberg, Germany). After 2 h
incubation at 37°C, cells were harvested from the lower
chamber compartment and counted by FACS analysis
using BD calibration beads.
Cytotoxicity assay
Freshly prepared DC preparations derived from the same
healthy individuals for both methods were tested for their
cytolytic activity against K562 target cells by flow cytome-
try. Before coculture, 1 × 106 K562 cells were labeled with
0.5  μM carboxyfluorescein diacetate succinimidyl ester
(CFDA-SE, Molecular probes, Paisley, UK) for 15 min. at
37°C. Different numbers of effector cells were cultured
with 1 × 105 labelled K562 cells in RPMI 1640 medium
containing 10% FCS. NK cells used as a positive control
were isolated from peripheral blood of a healthy donor
with a MACS NK cell separation kit (Miltenyi, Bergisch
Gladbach, Germany), and stimulated with 1000 U/ml IL-
2 (Chiron). The human lymphoma B cell line MHH-
PREB-1 (German Collection of Microorganisms and Cell
Cultures, Braunschweig, Germany) served as a negative
control. After 4 h of culture dead cells were stained with
propidium iodide (PI, Becton Dickinson) and analyzed
by flow cytometry. Specific lysis was determined by the
formula: % specific lysis = experimental % of PI+ CFDA-
SE labeled cells - spontanous % of PI+ CFDA-SE labeled
cells.
Identification of differential gene expression
Total RNA from DC preparations was isolated with the
RNeasy Mini kit (Qiagen, Hilden, Germany) according to
the manufacturer's recommendations. cRNA labelling,
hybridization to HG-Focus GeneChips (Affymetrix, UK,
Ltd.) and processing of the microarray data was per-
formed as described elsewhere [16]. Differential gene
expression was defined by a false discovery rate (FDR) of
5%, as indicated by a q-value ≤ 5% for individual genes.
To reduce the number of genes, we concentrated on genes
with a fold change ≥ 2 comparing both groups. For a spe-
cific analysis of NK cell markers, all differentially
expressed genes with q-values ≤ 5% were included.
RT-PCR analysis
cDNA was synthesized from the same RNA preparations
used for the microarray hybridizations as described [17],
and amplified using the Assays-on-Demand Gene Expres-
sion products on the ABI PRISM 7900HT sequence detec-
tion system instrument (Applied Biosystems, Applera
Deutschland GmbH, Darmstadt, Germany). For relative
quantification,  β2-microglobulin mRNA served as an
external standard. The following genes were detected by
Assays-on-Demand gene expression products: CCL8,
BCL2A1, GZMB, CCR7, LAMP3, PKR, ADAMDEC1,
FCGR1A, PDHA1, CCND2 and B2M. Relative gene
expression levels were expressed as the difference in Ct
values (deltaCt) of the target gene and B2M.
Statistical analysis
The results were analysed for statistical significance by a
two-sided, unpaired student's t-test for experiments with
independent samples and a two-sided, paired student's t-
test for paired samples. p-values < 0.05 indicate significant
differences.
Results
IFN-DC and IL-4/TNF-DC show typical DC characteristics
Viability and morphology
The resulting DC populations (n = 34) for both culture
conditions had a median purity of 84% as measured by
FSC/SSC characteristics and the proportion of CD11c and
HLA-DR positive cells. DC yield was equal with both
methods with a median proportion of 25% of the initial
monocyte count. As a result of the shorter culture period,
IFN-DC had a significantly greater viability than IL-4/
TNF-DC with median values of > 99% (n = 11) and 89%
(n = 7), respectively (p = 0.003).
IFN-DC and IL-4/TNF-DC had a similar morphology typ-
ical for DC. On the other hand, IFN-DC were smaller, less
granular and had a polarized distribution of cytoplasmic
protrusions, whereas IL-4/TNF-DC showed uniformly dis-
tributed protrusions (Fig. 1a).
Immunophenotypic characterization
The immunophenotypic analysis of IFN-DC and IL-4/
TNF-DC (n = 8 each) revealed a strong reduction of CD14
surface expression compared to monocytes (data notJournal of Translational Medicine 2007, 5:46 http://www.translational-medicine.com/content/5/1/46
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shown). Both DC populations had characteristic surface
markers for DC, expressing CD11c, CD86 and HLA-DR
(Fig. 1b). The proportion of cells positively staining for
the costimulatory molecules CD40 and CD80, was greater
among the population of IFN-DC than within the popu-
lation of IL-4/TNF-DC (CD40: 14 ± 9% vs 4 ± 4%, p =
0.01 and CD80: 49 ± 19% vs 22 ± 13%, p = 0.006). The
plasmacytoid DC marker CD123 was found on a signifi-
cantly greater proportion of IFN-DC in comparison to IL-
4/TNF-DC (72 ± 16% vs 36 ± 20%, p = 0.003), whereas
CD209, an adhesion molecule known to be expressed
exclusively on IL-4-DC, was not present on IFN-DC.
Allostimulatory capacity
IFN-DC (n = 4) as well as IL-4/TNF-DC (n = 4) induced
proliferation of allogeneic PBMC in a dose dependent
Phenotypical and functional characteristics of IFN-DC in comparison to IL-4/TNF-DC Figure 1
Phenotypical and functional characteristics of IFN-DC in comparison to IL-4/TNF-DC. (a) Morphology of IFN-DC (left) and IL-
4/TNF-DC (right). Cells were stained according to Pappenheim and viewed at x630 magnification. (b) Immunophenotypic anal-
ysis of IFN-DC and IL-4/TNF-DC. DC were gated according to their FSC/SSC characteristics. The results are summarized as 
mean ± SD of % PE positive CD45+ cells. (c) Stimulatory potential of DC in an allogeneic MLR. Different numbers of DC or 
monocytes were cocultured with 1 × 105 PBMC for 4 days in the presence of anti CD28 and CD49d antibodies. 3 [H]-Thymidin 
was added, and incorporated radioactivity was measured by β-scintillation. Results are expressed as the mean ± SD of the 
stimulation index. (d) Cytokine production of allogeneic T cells. Allogeneic PBMC were cocultured in a 2:1 ratio with mono-
cytes, IFN-DC or IL-4/TNF-DC or without any stimulus for three days. IFN-γ (left) and IL-4 (right) expression was detected by 
intracellular flow cytometry. The results are summarized as mean ± SD of % cytokine positive CD3+ cells after subtraction of 
background levels. (e) Migratory capacity of DC. Migration was measured in 24-well transwell culture chambers. Each well was 
loaded with 2.5 × 105 cells. The proportion of migrated cells towards Mip-3β as measured by flow cytometry is summarized as 
mean ± SD. Significant differences (p < 0.05) are marked by an asterisk. The brackets and asteriscs in c refer to the highest 
effector cell number.
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manner in an allogeneic MLR and stimulation was signif-
icantly higher with both DC populations in comparison
to monocytes (n = 5) (Fig. 1c).
Intracellular staining of IFN-γ and IL-4 in allogeneic T cells
after coculture with DC (Fig. 1d) revealed that both, IFN-
DC (n = 3) and IL-4/TNF-DC (n = 3), but not monocytes
(n = 2), could induce IFN-γ production in T cells. Moreo-
ver, IFN-DC but not IL-4/TNF-DC simultanously induced
also IL-4 production.
IFN-DC and IL-4/TNF-DC represent two distinct DC 
populations
In order to have a closer look at molecular differences
between IFN-DC and IL-4/TNF-DC, gene expression pro-
files of five DC preparations for each culture condition
were examined. We found 689 genes from a total of 8793
probe sets to be differentially expressed with a q-value <
5% and a fold change > 2. For corroboration, the differen-
tial expression of 10 genes detected by microarray tech-
nology was determined by quantitative real-time PCR for
three IFN-DC and IL-4/TNF-DC preparations each. The
more than twofold higher expression of 8 genes in IFN-
DC and two genes in IL-4/TNF-DC could be verified in
good accordance (Fig. 2b). Of the 689 differentially
expressed genes, 131 had a more than twofold greater
expression level in IFN-DC, while 558 genes were more
than twofold higher expressed in IL-4/TNF-DC (Addi-
tional file 2 and 3). Hierarchical cluster analysis for these
689 genes (Additional file 1) showed that IFN-DC and IL-
4/TNF-DC represent two distinct DC populations by a
strict grouping of IFN-DC versus IL-4/TNF-DC. In the fol-
lowing, we describe the differentially expressed genes by
assigning them to functional DC characteristics.
Signaling pathways of IFN-α, IL-4 and TNF-α
As expected, the cytokines used for the culture of IFN-DC
and IL-4/TNF-DC activated signaling pathways of IFN-α
or IL-4 and TNF-α, respectively. Transcription factors of
the IFN pathway, like STAT1, IRF7 and ISGF3G, were
expressed to a greater extent in IFN-DC as well as genes
coding for antiproliferative and antiviral effector mole-
cules like PKR, Mx1, oligoadenylate synthetases and other
typical interferon stimulated genes [18,19].
On the other hand, greater expression levels of genes
involved in IL-4 specific responses such as alterations of
lipid metabolism, chemotaxis, adhesion and phagocyto-
sis could be observed in IL-4/TNF-DC. These genes
include for example ALOX15, MDC, CD209, and FCER2
[20]. Similarly, typical TNF-α induced genes involved in
intracellular signaling and transcriptional regulation like
NFKBIA and EGR1 were higher expressed in IL-4/TNF-DC
[21].
Differences in the maturation status
In order to assess the maturation status of both DC popu-
lations we had a look at genes associated with phagocyto-
sis, antigen presentation and migration to the lymph
nodes as well as genes for proinflammatory mediators for
activation of immunocompetent cells. Looking at genes
involved in phagocytosis, which is associated with a more
immature DC phenotype, most of the differentially
expressed genes had greater levels in IL-4/TNF-DC, like
the genes for Ig receptors FCGRIIB, FCAR and FCER2,
complement components and receptors C1QA, C3 and
C1QR1, and the C-type lectins CD209 and CD205. IFN-
DC had only higher levels of the IgG receptor FCGR1A.
In regard to antigen presentation, there were no differ-
ences in the expression levels of MHC molecules and
other antigen presenting molecules. Some genes that par-
ticipate in lysosomal antigen processing were differen-
tially expressed. Of interest, the RNA level of the
lysosomal associated membrane protein DCLAMP which
is upregulated in mature DC [22], was higher in IFN-DC.
On the other hand, there were marked differences
between IFN-DC and IL-4/TNF-DC in the expression of
genes influencing migration and adhesion. IL-4/TNF-DC
showed a greater expression of genes involved in adhesion
to epithelium and inflammed tissue and T cell interaction
like integrin αE chain, CD97, and the β2 integrins CD18,
CD11b and CD11c. In contrast, IFN-DC had higher RNA
levels of the chemokine receptor CCR7 and the integrin
α4 chain, that play important roles in the migration of
mature DC to the lymph nodes [23,24]. Besides, they also
expressed higher RNA levels for molecules related to adhe-
sion to lymphoid tissue like sialoadhesin and decysin
[25,26], as well as the antiapoptotic protein bcl2A1 that
mediates survival of naïve T cells and is also expressed by
mature DC [27].
We confirmed this finding by functional analysis of the
migratory capacity of both DC populations on functional
level. IFN-DC (n = 4) showed a significantly 2.3 fold
greater proportion (p = 0.01) of migrated cells towards the
chemokine Mip-3β compared with IL-4/TNF-DC (n = 4)
(Fig. 1e).
Finally, IFN-DC and IL-4/TNF-DC also differentially
expressed proinflammatory mediators. IFN-DC had
greater RNA levels for the chemokines MCP1, MCP2 and
MCP3, potent attractors and activators of leukocytes [28],
as well as MIP2A, MIP2B and PPBP which more specifi-
cally attract innate effector cells [29,30]. This indicates
that IFN-DC may trigger a massive leukocyte migration.
IFN-DC had also higher RNA levels for ISG15, IFN-β, IL-4
and IL-1β converting enzyme, which further potentiate
IFN responses and contribute to the activation of NK cellsJournal of Translational Medicine 2007, 5:46 http://www.translational-medicine.com/content/5/1/46
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as well as B cells and T cells [12,31,32]. IL-4/TNF-DC
expressed a different set of chemokines, including MDC,
RANTES and Mip-3β, which are attractors especially of
activated T cells to inflammed tissues [28,33]. On the
other hand, IL-4/TNF-DC produced greater amounts of
RNA for enzymes of the lipid metabolism like ALOX5 and
ALOX15, that catalyze the synthesis of proinflammatory
leukotriens and other lipid metabolites, that are thought
to play a role in DC differentiation [34].
IFN-DC have novel molecular, phenotypical and functional characteristics in comparison to IL-4/TNF-DC Figure 2
IFN-DC have novel molecular, phenotypical and functional characteristics in comparison to IL-4/TNF-DC. (a) Hierarchical clus-
ter analysis of 52 genes related to NK cell function (rows) for IFN-DC and IL-4/TNF-DC preparations (columns) with expres-
sion levels obtained by Affymetrix microarray analysis. The colour scale indicates upregulation (green) and downregulation 
(red) of gene expression in relation to the mean expression levels of all preparations. (b) Corroboration of the microarray data 
by quantitative real-time PCR. The ΔCt values of 10 genes with β2-microglobulin as a reference gene were measured. Differ-
ences of the relative expression (mean ΔΔCt) of each gene were compared to the log2 of the fold change determined by 
microarray technology. (c) Expression of cytolytic effector molecules by DC. The intracellular expression of TRAIL and 
granzyme B by IFN-DC and IL-4/TNF-DC was analyzed by flow cytometry after permeabilization of cell membranes. The 
results are shown as mean ± SD of % positive cells. (d) Cytolytic activity of DC. Specific lysis of tumor cells by DC was meas-
ured by flow cytometric detection of propidium iodide uptake after coculture of 1 × 105 CFDA-SE labeled K562 cells with dif-
ferent numbers of IFN-DC and IL-4/TNF-DC as indicated by the effector : target ratios. IL-2 activated NK-cells were used as a 
positive, and B cells as negative control. Significant differences between IFN-DC and IL-4/TNF-DC at different effector : target 
ratios are indicated by an asterisk (p < 0.05).
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Cytotoxic capacity
The most intriguing result of the gene expression analysis
was the finding that IFN-DC expressed greater RNA levels
of cytotoxic effector molecules, like the granzymes B and
M, TRAIL and defensin-α1, which are important compo-
nents of the cytotoxic arsenal of NK cells [35,36]. There-
fore, we looked at 52 NK cell associated genes presented
by the microarray. Cluster analysis demonstrated a dis-
tinct expression profile of these genes by IFN-DC in com-
parison to IL-4/TNF-DC (Fig. 2a). Of these genes, 32 were
differentially expressed, all of them with significantly
higher levels in IFN-DC than in IL-4/TNF-DC such as
CD49b, KLRK1/NKG2D, NCR2/NKp44 and NCR1/
NKp46 (Table 1).
To corroborate these results, DC were further analyzed for
their cytotoxic capacity on protein level. TRAIL expression
(n = 6 for IFN-DC, n = 3 for IL-4/TNF-DC) was detected
intracellularly in almost all IFN-DC and in a significantly
lower proportion of IL-4/TNF-DC (94% vs 62%, p =
0.004) (Fig. 2c). In addition, the intracellular expression
of granzyme B (n = 3 each) was solely found in IFN-DC
(88% vs 1%, p < 0.001).
Further, these differences between IFN-DC and IL-4/TNF-
DC could also be demonstrated on a functional level. We
tested the cytotolytic activity of both DC preparations on
K562 cells by measurement of propidium iodide uptake.
Three DC preparations for each protocol were derived
from the same three healthy individuals and tested in
duplicates. IFN-DC displayed a significant dose depend-
ent cytotoxicity on K562 cells in a 4 h coculture experi-
ment as shown by a mean specific lysis of 26% at an
effector : target cell ratio of 20 : 1 (p = 0.006), 15% at 10 :
1 (p = 0.03) and 5% at 5 : 1 (p = 0.04), whereas IL-4/TNF-
DC did not show any specific cytotoxicity (Fig. 2d).
Discussion
DC based vaccines for patients with malignant diseases
generated under different culture conditions have been
investigated for more than a decade. Despite these efforts,
clinical results of DC vaccination studies showed thera-
Table 1: Genes involved in NK cell function with significantly higher expression in IFN-DC in comparison to IL-4/TNF-DC (q-value 
<5%)
Gene Symbol Gene Symbol Fold change
IL7R interleukin 7 receptor 8.66
TRAIL tumor necrosis factor (ligand) superfamily, member 10 5.02
DEFA1 defensin, alpha 1, myeloid-related sequence 4.64
GZMB granzyme B (cytotoxic T-lymphocyte-associated serine esterase 1) 3.33
GZMM granzyme M (lymphocyte met-ase 1) 2.09
KLRF1 killer cell lectin-like receptor subfamily F, member 1 1.91
LAG3 lymphocyte-activation gene 3 1.88
LTB lymphotoxin beta (TNF superfamily, member 3) 1.83
GZMA granzyme A (cytotoxic T-lymphocyte-associated serine esterase 3) 1.83
NKG7 natural killer cell group 7 sequence 1.77
CD2 CD2 antigen (p50), sheep red blood cell receptor 1.64
NCR2 natural cytotoxicity triggering receptor 2 1.55
IL2RB interleukin 2 receptor, beta 1.53
IL12RB2 interleukin 12 receptor, beta 2 1.48
KLRC3 killer cell lectin-like receptor subfamily C, member 3 1.45
NCR1 natural cytotoxicity triggering receptor 1 1.45
NK1 CD160 antigen 1.42
KIR3DL2 killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 1.41
KLRA1 killer cell lectin-like receptor subfamily A, member 1 1.34
IL12RB1 interleukin 12 receptor, beta 1 1.33
KIR2DS1 killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 1 1.33
CD96 CD96 antigen 1.33
FasL tumor necrosis factor (ligand) superfamily, member 6 1.32
CD49b integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 1.30
CXCR3 chemokine (C-X-C motif) receptor 3 1.27
KIR2DL1 killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 1 1.27
CD56 neural cell adhesion molecule 1 1.27
KLRK1 killer cell lectin-like receptor subfamily K, member 1 1.27
IFNG interferon, gamma 1.21
IL15RA interleukin 15 receptor, alpha 1.21
KIR2DS3 killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 3 1.19
KLRG1 killer cell lectin-like receptor subfamily G, member 1 1.19Journal of Translational Medicine 2007, 5:46 http://www.translational-medicine.com/content/5/1/46
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peutic efficacy only in a limited number of patients so far
[4]. In search of an alternative way for DC generation we
examined the molecular and functional characteristics of
IFN-DC in comparison to IL-4/TNF-DC.
We could show that both, IFN-DC and IL-4/TNF-DC, dis-
play typical DC characteristics, but also have distinct
molecular and functional phenotypes, as a reflection of
the distinct transcriptional signature of IFN-α in compar-
ison to other cytokines as recently described [19]. Our
results from gene expression analysis confirm previous
reports that IFN-DC have signs of a pronounced matura-
tion state and an increased migratory capacity to the
lymph nodes in comparison to IL-4/TNF-DC [8,10]. Strik-
ingly, IFN-DC showed a more plasmacytoid phenotype
associated with NK cell characteristics on molecular and
protein level as well as a functional cytotoxic activity
against tumor cells. Therefore, the use of IFN-DC in vacci-
nation trials may result in a better clinical antitumor
immune response.
As others have shown before [6-11], IFN-DC in our study
had a DC morphology and immunophenotype with high
levels of CD11c, CD86 and HLA-DR as well as functional
DC characteristics like the capacity to stimulate T cells.
The expression of costimulatory molecules was in accord-
ance to other studies using serumfree culture conditions
[37]. Nevertheless, we found a stronger upregulation of
the costimulatory molecules CD40 and CD80 on IFN-DC
than on IL-4/TNF-DC, although IFN-DC did not mediate
an increased allostimulatory reaction. Further, IFN-DC
triggered a balanced Th1/Th2 response, whereas IL-4/
TNF-DC were strongly biased to evoke a Th1 response.
This is in line with Lapenta et al., 2003 and 2006, who
showed that IFN-DC could induce a massive humoral and
cellular immune response [9,38].
In addition, the greater RNA levels for cytokines and
chemokines in IFN-DC like IFN-β, MCPs, MIP2A and
MIP2B as well as the IL-1β converting enzyme (CASP1)
that catalyzes the secretion of active forms of IL-1β and IL-
18, suggest that IFN-DC may also recruit other innate
cytotoxic effectors like NK cells [12,28,29,31,32] and neu-
trophils [29,30].
It is well accepted that a pronounced DC maturation sta-
tus is important for the induction of efficient immune
responses by DC immunotherapy [39]. In our study, both
DC preparations showed only marginal upregulation of
the maturation marker CD83, which is a result from cul-
ture conditions using serum free medium [37]. Gene
expression analysis revealed that IL-4/TNF-DC have more
immature DC characteristics. This was indicated by the
higher expression of several genes envolved in phagocyto-
sis such as Fc and complement receptors as well as genes
envolved in epithelial adhesion structure formation
including the genes for vinculin or the integrin αE chain.
In contrast to this finding, IFN-DC showed a higher
expression of several alternative DC maturation markers
than IL-4/TNF-DC that are involved in antigen processing
(DCLAMP [22]), migration to and localization in the
lymph nodes (CCR7 [23], integrin α4 [24] and decysin
[26]) as well as survival (BCL2A1 [27]). Therefore, on
molecular level, IFN-DC show the prerequisite to initiate
an adaptive immune response in the lymph node [1,39].
Importantly, this capacity of IFN-DC could be demon-
strated functionally by a higher migratory capacity of IFN-
DC in vitro compared to IL-4/TNF-DC as shown by tran-
swell experiments. This is also in line with Parlato et al.,
2001, who had shown before that IFN-DC have a higher
migratory potency than IL-4-DC not stimulated by TNF-α
[8].
Interestingly, the higher expression of genes of the IFN
pathway like the transcription factors STAT1 and IRF7 as
well as PKR, and IFN-β in IFN-DC resembles the expres-
sion pattern of plasmacytoid DC [40-43] that are the
major type I IFN producers during viral infections [44].
We found high surface levels of the plasmacytoid DC
marker CD123 and low levels of the myeloid DC marker
CD209 on IFN-DC, which is in line with Mohty et. al.,
2003, who also described other plasmacytoid DC markers
like TLR7 on IFN-DC [45].
The most important new finding of our study was the sig-
nificant upregulation of 32 genes strongly related to NK
cell functions in IFN-DC compared to IL-4/TNF-DC.
These include NK cell receptors NKp80, NKp44, NKp46
and NKG2D that are synergizing the cytotoxic activity of
NK cells [46,47], as well as CD56 and cytotoxic effector
molecules such as granzymes and TRAIL. Indeed, on pro-
tein level, we could detect intracellular pools of TRAIL and
granzyme B in IFN-DC. Finally, as a further corroboration
of the suggested cytotoxic capacity, IFN-DC but not IL-4/
TNF-DC were able to kill K562 cells in vitro. This is in con-
cordance with the previously made observation that DC
can kill tumor cells by TRAIL mediated lysis [7,48]. Still,
the expression of granzymes might further argue for a per-
forin mediated killing mechanism by IFN-DC.
These findings are of particular interest, as a new murine
DC cell population has been recently described, termed
interferon-producing killer dendritic cells (IKDC), that
express molecular markers of plasmacytoid DC and NK
cells [49,50]. IKDC exhibit specific cytolytic activity upon
contact with tumor cells or activation with CpG oligonu-
cleotides and subsequently upregulate costimulatory mol-
ecules, migrate to the lymph nodes and present antigen to
T cells. Indeed, 9 of the genes specifically expressed by
IKDC including granzymes, NKG2D, NKp46, and CD49bJournal of Translational Medicine 2007, 5:46 http://www.translational-medicine.com/content/5/1/46
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as detemined by microarray analsysis [49], were also dif-
ferentially expressed by IFN-DC in comparison to IL-4/
TNF-DC. Together with the pronounced migratory poten-
tial and the cytotoxic capacity of IFN-DC, the similarities
between IFN-DC and mouse IKDC suggest that also in
humans a molecular and functional relationship exists
between DC and NK cells.
Conclusion
In conclusion, the results of this study convey the idea,
that IFN-α does not only induce DC differentiation. It fur-
ther triggers maturation of a distinct DC type with NK cell
properties that is not only capable of inducing a specific
primary antitumor response in the lymph nodes but also
mediates an innate immune response. IFN-DC can not
only stimulate T cells but can kill tumor cells by them-
selves. Due to these new functional properties, IFN-DC
are a promising alternative for vaccination strategies, that
should be evaluated in clinical trials.
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